Trial Search Results

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individuals to developing a very serious cancer that is linked to Epstein-Barr virus (EBV).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator: Clinical Trials in Organ Transplantation in Children


  • Procedure: transplant
  • Drug: Immunosuppressive Drugs


Inclusion Criteria:

   - Subject and/or parent or legal guardian must be able to understand and provide
   informed consent/assent;

   - Candidate for or recipient of: heart, liver, heart with liver, small intestine, liver
   with small intestine, or kidney; and

   - Subject enrolled within 3 years of transplant.

Exclusion Criteria:

   - Previous diagnosis of PTLD;

   - Transplant recipients of lung alone, or in combination with an eligible organ type;

   - Pancreas transplantation with the exception of 'en bloc' transplant in combined liver
   and small intestine multivisceral transplantation;

   - Any combination other than listed in inclusion criteria;

   - History of any previous solid organ, stem cell, or bone marrow transplantation;

   - Inability or unwillingness of the legal guardian and/or the subject to comply with the
   study protocol.

Ages Eligible for Study

N/A - 21 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sheri Krams, PhD
Not Recruiting